CARPOOL Radial Access as Good as Femoral in PAD Procedures

Why It Matters

Demonstrating radial access as a safe, efficient alternative could reshape PAD procedural standards, improving patient recovery and expanding market demand for radial‑compatible devices.

Key Takeaways

• Radial access shows non‑inferior 30‑day MALE rates.
• Technical success slightly lower for radial (87% vs 95%).
• Hospital stay reduced to 5 hours with radial.
• Device availability limits radial use in complex lesions.
• Randomized trials needed to confirm observational findings.

Pulse Analysis

Radial‑to‑peripheral (R2P) access is emerging as a viable route for peripheral artery disease interventions, mirroring the earlier transition seen in coronary procedures. Early data from the CARPOOL registry suggest that, despite a modest dip in technical success compared with traditional femoral access, radial entry delivers comparable short‑term limb outcomes while dramatically shortening inpatient time. This shift aligns with broader trends toward minimally invasive strategies that prioritize patient comfort, early ambulation, and reduced procedural overhead.

The study’s propensity‑matched cohorts of 273 patients each revealed a 87.2% technical success rate for radial access versus 94.9% for femoral, yet the radial group benefitted from a five‑hour median hospital stay versus a full day for femoral. Access‑site switching was more frequent with radial, reflecting current limitations in device sizing and availability, especially for atherectomy tools. Operators tend to reserve radial for lesions in the iliac and common femoral arteries, while femoral remains preferred for superficial femoral disease where larger sheaths are required.

If larger, randomized trials confirm these findings, the procedural landscape could shift toward algorithms that prioritize radial access for suitable PAD cases, driving demand for industry‑backed long‑shaft, low‑profile equipment. Such a transition would not only enhance patient satisfaction and lower healthcare costs but also stimulate competition among the seven companies already offering R2P solutions. The upcoming six‑month and one‑year follow‑ups will be critical in determining whether radial access can move from a niche technique to a new standard of care.